1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Generics in Indonesia

Generics in Indonesia

  • January 2016
  • -
  • MarketLine
  • -
  • 32 pages

Introduction

Generics in Indonesia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Indonesia generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

- For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

- The Indonesian generics market is expected to generate total revenues of $0.9bn in 2015, representing a compound annual growth rate (CAGR) of 17.9% between 2011 and 2015.

- Market consumption volume is forecast to reach a total of 49.5 % of total pharma volume in 2015.

- The Indonesian market should continue to see strong growth as the country’s first compulsory national health insurance system, which aims to make basic care available to every citizen by 2019, was launched in January 2014.

Features

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Indonesia

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Indonesia

- Leading company profiles reveal details of key generics market players’ global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Indonesia generics market with five year forecasts by both value and volume

- Macroeconomic indicators provide insight into general trends within the Indonesia economy

Key Questions Answered

- What was the size of the Indonesia generics market by value in 2015?

- What will be the size of the Indonesia generics market in 2020?

- What factors are affecting the strength of competition in the Indonesia generics market?

- How has the market performed over the last five years?

- How large is Indonesia’s generics market in relation to its regional counterparts?

Table Of Contents

Generics in Indonesia
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market volume 9
Market Segmentation 10
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Market volume forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
PT Kalbe Farma Tbk 19
PT Indofarma (Persero), Tbk 22
PT Sanbe Farma 25
PT Soho Global Health 26
Macroeconomic Indicators 27
Country Data 27
Methodology 29
Industry associations 30
Related MarketLine research 30
Appendix 31
About MarketLine 31

List of Tables
Table 1: Indonesia generics market value: $ billion, 2011-15(e)
Table 2: Indonesia generics market volume: % of total pharma volume, 2011-15(e)
Table 3: Indonesia generics market geography segmentation: $ billion, 2015(e)
Table 4: Indonesia generics market value forecast: $ billion, 2015-20
Table 5: Indonesia generics market volume forecast: % of total pharma volume, 2015-20
Table 6: PT Kalbe Farma Tbk: key facts
Table 7: PT Kalbe Farma Tbk: key financials ($)
Table 8: PT Kalbe Farma Tbk: key financials (IDR)
Table 9: PT Kalbe Farma Tbk: key financial ratios
Table 10: PT Indofarma (Persero), Tbk: key facts
Table 11: PT Indofarma (Persero), Tbk: key financials ($)
Table 12: PT Indofarma (Persero), Tbk: key financials (IDR)
Table 13: PT Indofarma (Persero), Tbk: key financial ratios
Table 14: PT Sanbe Farma: key facts
Table 15: PT Soho Global Health: key facts
Table 16: Indonesia size of population (million), 2011-15
Table 17: Indonesia gdp (constant 2005 prices, $ billion), 2011-15
Table 18: Indonesia gdp (current prices, $ billion), 2011-15
Table 19: Indonesia inflation, 2011-15
Table 20: Indonesia consumer price index (absolute), 2011-15
Table 21: Indonesia exchange rate, 2011-15

List of Figures
Figure 1: Indonesia generics market value: $ billion, 2011-15(e)
Figure 2: Indonesia generics market volume: % of total pharma volume, 2011-15(e)
Figure 3: Indonesia generics market geography segmentation: % share, by value, 2015(e)
Figure 4: Indonesia generics market value forecast: $ billion, 2015-20
Figure 5: Indonesia generics market volume forecast: % of total pharma volume, 2015-20
Figure 6: Forces driving competition in the generics market in Indonesia, 2015
Figure 7: Drivers of buyer power in the generics market in Indonesia, 2015
Figure 8: Drivers of supplier power in the generics market in Indonesia, 2015
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Indonesia, 2015
Figure 10: Factors influencing the threat of substitutes in the generics market in Indonesia, 2015
Figure 11: Drivers of degree of rivalry in the generics market in Indonesia, 2015
Figure 12: PT Kalbe Farma Tbk: revenues and profitability
Figure 13: PT Kalbe Farma Tbk: assets and liabilities
Figure 14: PT Indofarma (Persero), Tbk: revenues and profitability
Figure 15: PT Indofarma (Persero), Tbk: assets and liabilities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.